Skip to content

Short- and Long-Term Effects of Antibiotics on Childhood Growth

The Patient-Centered Outcomes Research Network (PCORnet) Obesity Observational Study: Short- and Long-Term Effects of Antibiotics on Childhood Growth

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02744846
Acronym
ABX
Enrollment
681739
Registered
2016-04-20
Start date
2016-02-29
Completion date
2018-12-31
Last updated
2019-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

antibiotics, children, pediatric, body mass index, Observational Study, Comparative Effectiveness Research, Obesity, Growth Trajectory, Cohort Study, Electronic Medical Record, Qualitative Research

Brief summary

The objectives of the proposed study are to assess the effects of different types, timing, and amount of antibiotic use in the first two years of life with (Specific Aim 1) body mass index (BMI) and obesity at ages 5 and 10 years and (Specific Aim 2) growth trajectories to age 5 years. In Specific Aim 3, the investigators will address how big the effects of antibiotics on obesity are within subgroups of the population, such as different racial/ethnic groups and whether the child's mother got antibiotics while she was pregnant. The data for this study will come from electronic medical records of about 600,000 children from 42 healthcare systems within 10 Clinical Data Research Networks (CDRNs) across the United States. The investigators will get information on antibiotic prescribing in the first two years of life, then virtually follow these children to ages 5 and 10 years to see what their BMIs are, and how many of them are obese by clinical standards (i.e., body mass index exceeding the 95th percentile for age and sex). In the main analyses, the CDRNs will not send any individual data to a central site. Rather, using sophisticated computer programs, the study's coordinating center will send questions to the data, thus protecting the privacy of patients' and the healthcare systems' records. In some analyses, to check how well this distributed research network approach works, we will work with individual records whose identifying information has been stripped off (de-identified data). In our Secondary Aim, the investigators will employ focus groups of parents and in-depth interviews with clinicians to explore how best to put the findings into everyday practice. Throughout the study, in addition to employing privacy-protecting approaches to analyzing and sharing data, the investigators will adhere to principles of inclusion, patient-centeredness, stakeholder engagement, effective governance, and protection of human subjects. At the end of the two-year project, the investigators will propose avenues for dissemination of the scientific findings and other products.

Detailed description

Antibiotics are among the most valuable medical discoveries. Recent research on understanding of how bacteria in our gut use energy, however, raises concerns about whether broad-spectrum antibiotics, which are over-prescribed for mild infections, prescribed in early infancy may cause obesity during childhood. Obesity is a very common and serious condition among US children, particularly children from disadvantaged populations. Past studies examining the link between antibiotic use and childhood obesity are too small and they lack diversity as well as modern scientific tools to gauge the extent to which prescribing antibiotics can lead to excess weight gain. PCORnet, the National Patient-Centered Clinical Research Network, comprising very large networks of data from electronic medical records, provides an ideal test bed to address this question. Further, it is not clear how caregivers and clinicians will use the results of earlier studies to decide which antibiotics to prescribe when faced with common infections like ear infections. Specific Aim 1: To evaluate the comparative effects of different types, timing, and amount of antibiotics used during the first two years of life on body mass index and risk of obesity at ages 5 (primary outcome age) and 10 (secondary) years. Hypothesis: There will be a dose-response relationship between the number of antibiotic courses given during the first 2 years of life and both higher BMI and the probability of obesity at ages 5 and 10 years. This relationship will be strongest for broad-spectrum antibiotics prescribed in the first 6 months of life. Specific Aim 2: To assess the comparative effects of different types, timing, and amount of antibiotics used during the first two years of life on the rates and patterns of childhood growth during the first 5 years of life. Hypothesis: There will be a dose-response relationship between the number of antibiotic courses given during the first 2 years of life and subsequent growth trajectories of children in a pattern that increases children's risk of later overweight and obesity. This relationship will be strongest for broad-spectrum antibiotics prescribed in the first 6 months of life. Specific Aim 3: To explore how the effects of different types, timing, and amount of antibiotics on childhood BMI, obesity risk and growth (Aims 1 and 2) vary according to patient socio-demographic, clinical, and maternal characteristics, including: 1) socio-demographic (Child sex, Child race/ethnicity, Geography, based on location of clinical facility); 2) Clinical (Prescription of medications that also cause obesity, esp. corticosteroids, Low birth weight or macrosomia in term infants); 3) Maternal for the subset of data partners listed in section B above that have linked maternal and child records (BMI, Maternal receipt of antibiotics during pregnancy, Type of delivery, i.e., Cesarean v. vaginal). Hypotheses: The antibiotic effects will not vary by socio-demographic or maternal characteristics. Long-term corticosteroid use will potentiate the effect of antibiotics on childhood obesity. Secondary Aim: Through focus groups and in-depth interviews, to explore how parents and other caregivers and their providers assess information related to current and future benefits and risks, particularly for treatments such as antibiotics in early childhood, which can have substantial near-term benefits along with moderate long-term risks. The investigators will also explore how clinicians, health care organizations, and policy makers should best present study findings to help parents understand its strengths and limitations in the context of shared clinical decision-making.

Interventions

DRUGAntibiotics exposure

Sponsors

Patient-Centered Outcomes Research Institute
CollaboratorOTHER
National Patient-Centered Clinical Research Network
CollaboratorOTHER
ADVANCE CDRN
CollaboratorUNKNOWN
Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN)
CollaboratorOTHER
Greater Plains Collaborative Clinical Data Research Network
CollaboratorOTHER
Mid-South Clinical Data Research Network
CollaboratorOTHER
New York City Clinical Data Research Network
CollaboratorOTHER
OneFlorida Clinical Research Consortium
CollaboratorOTHER
PEDSnet: A Pediatric Learning Health System CDRN
CollaboratorUNKNOWN
PORTAL CDRN
CollaboratorUNKNOWN
Research Action for Health Network (REACHnet)
CollaboratorOTHER
Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS)
CollaboratorUNKNOWN
Genetic Alliance
CollaboratorOTHER
StatLog
CollaboratorUNKNOWN
Harvard Pilgrim Health Care
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 11 Years
Healthy volunteers
No

Inclusion criteria

1. 1 or more encounters with length and weight measured in each of the following age intervals: 0-12 months, 12-30 months, and 2. 1 or more encounters with height and weight measured after 24 months of age (need 1 or more measure at 4.0-5.9 years for the 5 year outcome and 1 or more measure at 9.0 to 10.9 years for the 10 year outcome), or eligible to be followed to these ages using multiple imputation to account for missing data.

Exclusion criteria

1\. Biologically implausible length/height or weight measurements

Design outcomes

Primary

MeasureTime frameDescription
Body Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 Months48-72 MonthsBMI z-score measured between 48-72 months Body mass index z-scores are measures of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Positive values below indicate a higher BMI z-score in children who received antibiotics versus those who did not.
Body Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 Months10 yearsBMI measured at 10 years Body mass index z-scores are measures of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Positive values below indicate a higher BMI z-score in children who received antibiotics versus those who did not.

Participant flow

Participants by arm

ArmCount
Children From Birth to 5 Years
Children from birth to 5 years where: 1. 1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and 2. \> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data Antibiotics exposure
681
Total681

Baseline characteristics

CharacteristicChildren From Birth to 5 Years
Age, Customized
Less than 12 months
681,739 Participants
Birth-related diagnoses
Heavy for gestational age newborn
9,907 Participants
Birth-related diagnoses
Low birth weight
5,828 Participants
Birth-related diagnoses
Macrosomia
425 Participants
Birth-related diagnoses
No birth diagnosis
612,827 Participants
Birth-related diagnoses
Prematurity
52,752 Participants
Chronic conditions/categories
Asthma
94,399 Participants
Chronic conditions/categories
Cardiovascular
46,862 Participants
Chronic conditions/categories
Endocrine
6,602 Participants
Chronic conditions/categories
Gastrointestinal
6,015 Participants
Chronic conditions/categories
Hematological/immunological
14,547 Participants
Chronic conditions/categories
Malignant neoplasms
6,593 Participants
Chronic conditions/categories
Metabolic
17,005 Participants
Chronic conditions/categories
Neuromuscular
16,906 Participants
Chronic conditions/categories
No chronic condition diagnosis
392,864 Participants
Chronic conditions/categories
Other congenital defect
42,094 Participants
Chronic conditions/categories
Renal
16,397 Participants
Chronic conditions/categories
Respiratory
21,455 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
119,059 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
445,878 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
116,802 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2,862 Participants
Race (NIH/OMB)
Asian
28,356 Participants
Race (NIH/OMB)
Black or African American
170,007 Participants
Race (NIH/OMB)
More than one race
14,184 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
2,930 Participants
Race (NIH/OMB)
Unknown or Not Reported
99,641 Participants
Race (NIH/OMB)
White
363,759 Participants
Sex: Female, Male
Female
324,864 Participants
Sex: Female, Male
Male
356,875 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 0
other
Total, other adverse events
0 / 00 / 0
serious
Total, serious adverse events
0 / 00 / 0

Outcome results

Primary

Body Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 Months

BMI measured at 10 years Body mass index z-scores are measures of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Positive values below indicate a higher BMI z-score in children who received antibiotics versus those who did not.

Time frame: 10 years

ArmMeasureGroupValue (MEAN)
Children With no Complex Chronic ConditionsBody Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 MonthsAny antibiotics vs. none <24 months of age0.03 BMI z-score units
Children With no Complex Chronic ConditionsBody Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 MonthsBroad spectrum vs. none < 24 months of age0.04 BMI z-score units
Children With no Complex Chronic ConditionsBody Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 MonthsNarrow spectrum vs. non <24 months of age0.02 BMI z-score units
Children With Complex Chronic ConditionsBody Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 MonthsAny antibiotics vs. none <24 months of age0.09 BMI z-score units
Children With Complex Chronic ConditionsBody Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 MonthsBroad spectrum vs. none < 24 months of age0.08 BMI z-score units
Children With Complex Chronic ConditionsBody Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 MonthsNarrow spectrum vs. non <24 months of age0.08 BMI z-score units
Primary

Body Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 Months

BMI z-score measured between 48-72 months Body mass index z-scores are measures of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Positive values below indicate a higher BMI z-score in children who received antibiotics versus those who did not.

Time frame: 48-72 Months

ArmMeasureGroupValue (MEAN)
Children With no Complex Chronic ConditionsBody Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 MonthsBroad spectrum vs. none < 24 months of age0.04 BMI z-score units
Children With no Complex Chronic ConditionsBody Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 MonthsAny antibiotics vs. none <24 months of age0.04 BMI z-score units
Children With no Complex Chronic ConditionsBody Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 MonthsNarrow spectrum vs. non <24 months of age0.02 BMI z-score units
Children With Complex Chronic ConditionsBody Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 MonthsAny antibiotics vs. none <24 months of age0.06 BMI z-score units
Children With Complex Chronic ConditionsBody Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 MonthsBroad spectrum vs. none < 24 months of age0.07 BMI z-score units
Children With Complex Chronic ConditionsBody Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 MonthsNarrow spectrum vs. non <24 months of age0.03 BMI z-score units

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026